Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6793MR)

This product GTTS-WQ6793MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, DS-8201(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ6793MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11773MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MK-3222
GTTS-WQ7140MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ5716MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CEA TCB
GTTS-WQ8373MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ3259MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ10601MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ13451MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ9715MR IVTScrip™ mRNA-Anti-CD3E&GPRC5D, JNJ-64407564(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64407564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW